Immune response to inactivated influenza virus vaccine: antibody reactivity with epidemic influenza B viruses of two highly distinct evolutionary lineages.
Vaccination of adults (healthy female employees potentially capable of transmitting influenza to high-risk persons; n = 104) in autumn 1990 with a trivalent influenza virus vaccine containing B/Yamagata/16/88 induced a low antibody response to B/Finland/150/90, a recent variant of B/Victoria/2/87-like viruses, as compared with the antibody response to B/Finland/172/91, a current variant in the lineage of B/Yamagata/16/88-like viruses. Up to the end of the epidemic season, the antibody status declined but was still significantly better than before the vaccination. The results suggest that the vaccine strain was appropriate for the outbreak of 1990 to 1991 in Finland, but may provide unsatisfactory protection against B/Victoria/2/87-like viruses. Evidence is given that use of Madin-Darby canine kidney (MDCK)-grown virus as an antigen in the haemagglutination inhibition test (HI) may provide more reliable information about the protective antibodies than use of untreated or ether-treated egg-grown viruses. Significantly higher postvaccination and postepidemic antibody titres were recorded among subjects who exhibited the antibody before vaccination than among seronegative subjects. A significantly higher response rate among initially seronegative people than among seropositive people was recorded for antibody to B/Finland/150/90, but no clear evidence was obtained that the pre-existing antibody could have had a negative effect on the antibody production.
Pyhälä
R
R
National Public Health Institute, Helsinki, Finland.
Kleemola
M
M
Kumpulainen
V
V
Vartiainen
E
E
Lappi
S
S
Pönkä
A
A
Cantell
K
K
D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000097:blood; D000956:Antigens, Viral / Q000145:classification; D004196:Disease Outbreaks; D005260:Female; D005387:Finland / Q000453:epidemiology; D006801:Humans; D009981:Influenza B virus / Q000145:classification / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology* / Q000627:therapeutic use; D007251:Influenza, Human / Q000453:epidemiology / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D014613:Vaccines, Attenuated / Q000276:immunology / Q000627:therapeutic use
D000914:Antibodies, Viral; D000956:Antigens, Viral; D007252:Influenza Vaccines; D014613:Vaccines, Attenuated